ATXN1 and spinocerebellar ataxia type 1: YAP∆C-ins61 had the strongest anti-TRIAD activity and the therapeutic use of YAP∆C-ins61 in a mouse model of spinocerebellar ataxia type 1 (SCA1) found that expression of YAP∆C-ins61 in development, as opposed to during adulthood was required to ameliorate the pathology and symptoms of SCA1 (ataxin-1 knock-in mutant) mice [78].